Waterhouse is due to take the helm of CSL on 1st February next year, around a year after Paul McKenzie abruptly departed the ...

Hibsago, has been approved in the US, its second major market after Japan, giving patients hope of a functional cure without ...

Despite a string of US policy initiatives designed to curb medicine pricing under recent administrations, the annual cost of ...

That one chance rests on a set of decisions about data and the systems that hold it. Those decisions are usually made quickly ...

While relatively uncommon, UC that starts in childhood tends to be more extensive and severe than when it emerges in ...

The FDA has published its long-awaited update to guidance to make sure clinical trials more closely reflect the range of patients that might be treated with a new therapy in the real world. The draft ...

Novo continues to build the case for its new weight-loss candidate CagriSema, pointing to new data that show strong efficacy ...

The EMA's human medicines committee has started a review of oral complement C5 inhibitor Tavneos, prompted by information that the regulator says raises questions about the integrity of the data from ...

US MFN rules and new tariffs are narrowing the US–ex-US price gap and drawing more manufacturing and capital investment toward the United States. Low European or UK list prices now directly affect US ...

A year after signing a first deal with Hansoh worth up to $1.45 billion, Roche has returned for another that could be more ...

A compounded version of Eli Lilly's injectable weight-loss and diabetes therapy tirzepatide, produced and sold by Apothecary ...

Merck KGaA has reached a deal to acquire UK-based Silence Therapeutics in ​an all-cash, $1.3 billion deal that will boost its ...